Company intelligence / Profile preview

CHD Bioscience

Fort Collins, Colorado, United Stateslinkedin.com ↗

Ownership: Private
Development stage: Phase 2

Overview

CHD Bioscience has developed a technology platform for antimicrobial agents, with lead product VERIOX demonstrating preclinical and possibly early clinical signs of safety and efficacy against drug-resistant pathogens; targeting prevention and treatment of serious, resistant infections, with efforts focused on wound, orthopedic, and topical infection segments[1][2][3][7].

Therapeutic areas: Infectious DiseasesNeurologyDermatology
Modalities: Small moleculeTopical agent
Industry: Biotech

Drug pipeline

1 asset

VERIOX

Phase 2

Indications: Drug-resistant infections

Partnerships

Colorado State University

Beyond the preview

Go deeper on CHD Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHD Bioscience.

Explore the full profile